Minnesota is currently home to 2089 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Prophylactic Antibiotics in Cystectomy With Diversion
NCT06190197
Recruiting
Using a randomized 2 arm design, this study is being conducted to test for non-inferiority of no prophylactic antibiotic therapy versus the prophylactic oral antibiotic, nitrofurantoin, through comparison of rates of postoperative urinary tract infections within the 90-day postoperative period in patients with muscle invasive bladder cancer who undergo radical cystectomy with urinary diversion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Muscle-Invasive Bladder Carcinoma, Radical Cystectomy, Ileal Conduit, Neobladder Diversion
Register for Updates
BLOODSAFE Ghana- Iron and Nutritional Counselling Strategy
NCT06101238
Recruiting
A randomized trial will compare 6-months of low-dose (65mg elemental iron daily) among prospective blood donors who are deferred for low haemoglobin but have passed all of the other pre-screening requirements for blood donation to a group of donors who were deferred from donating and receive the current standard of care (nutrition counseling only). An automated full blood count (FBC) will also be done to identify any safety concerns. The randomized trial will evaluate effectiveness with the prim... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
04/15/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Blood Donation
Register for Updates
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
NCT06007690
Recruiting
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
Register for Updates
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
NCT06005493
Recruiting
This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Research Site, Rochester, Minnesota
Conditions: Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
Register for Updates
Aim 3 Particle Swarm Optimization PIGD
NCT05934747
Recruiting
In Parkinson's disease (PD) patients undergoing standard-of-care Deep Brain Stimulation (DBS) therapy, to compare the effect on Parkinson's symptoms of two different neurostimulator settings designed to differ from each other as much as possible with respect to how much they activate two different neuroanatomical structures: the axonal pathway from Globus Pallidus (GP) to Pedunculopontine Nucleus (PPN), and the axonal pathway from PPN to GP.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/15/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Parkinson's Disease and Parkinsonism
Register for Updates
Remotely Delivered Cognitive Multisensory Rehabilitation for Sensory and Motor Recovery After Spinal Cord Injury
NCT05870189
Recruiting
So far, therapies have limited success in functional recovery in adults with chronic SCI. By introducing remote cognitive multisensory rehabilitation (CMR), which has shown significant functional improvements due to neurological recovery when delivered in-person, transformative results that (i) provide a potentially effective new therapy within the healthcare system, accessible to more patients, and (ii) demonstrate brain function changes alongside improved function in chronic SCI are anticipate... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/15/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Spinal Cord Injuries, Spinal Cord Diseases
Register for Updates
Udall Project 1 Aim 4
NCT05568199
Recruiting
By defining the strength and direction of connectivity patterns at rest and during movement across the basal ganglia-thalamocortical (BGTC) network we will characterize the role of individual circuits in motor performance and cognitive function, paving the way for future development of optimization algorithms for DBS that take advantage of this understanding.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/15/2025
Locations: University Of Minnesota, Minneapolis, Minnesota
Conditions: Parkinsons Disease, Deep Brain Stimulation
Register for Updates
Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)
NCT05417789
Recruiting
This is a multicenter, Phase 3, randomised, double-blind, placebo-controlled study, which aims to evaluate the efficacy and safety of the investigational drug emactuzumab for the treatment of patients with localized or diffuse TGCT where surgical removal of the tumor is not viewed as an option. The study consists of two parts. In Part 1, eligible subjects will be assigned in a 2:1 ratio to receive either emactuzumab or matching placebo in a double-blind fashion, that will be administered in tot... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/15/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: TGCT
Register for Updates
Intracranial Stimulation Mapping In Epilepsy
NCT05290610
Recruiting
This is a single group prospective study to determine the feasibility for generating brain maps that localize cerebral functions and inter-regional information flow in partial epilepsy in adult patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Epilepsy
Register for Updates
Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
NCT04523727
Recruiting
This study will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney disease (CKD).
Gender:
ALL
Ages:
Between 6 years and 16 years
Trial Updated:
04/15/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Hyperphosphatemia Related to Chronic Kidney Disease
Register for Updates
Geniculate Artery Embolization for Osteoarthritis
NCT04456569
Recruiting
The need for exploration of more definitive and cost effective non-arthroplasty treatments of osteoarthritis (OA) has been demonstrated by the orthopedic and health economic research. Embolotherapy of neovessels associated with OA joints has been shown to be promising in patients with knee OA. There is a need for level one evidence drawn from randomized clinical trials to prove the safety, feasibility and efficacy of knee embolotherapy compared to standard of care. This randomized pilot study... Read More
Gender:
ALL
Ages:
Between 40 years and 70 years
Trial Updated:
04/15/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Osteo Arthritis Knee, Arthritis, Osteoarthritis, Osteoarthritis, Knee
Register for Updates
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
NCT04067336
Recruiting
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess ziftomenib, a menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib will continue in patients with NPM1-m AML.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia
Register for Updates